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Association of cardiovascular health 
and epigenetic age acceleration
Tess D. Pottinger1,14* , Sadiya S. Khan2,3, Yinan Zheng2, Wei Zhang2, Hilary A. Tindle4,5, Matthew Allison6, 
Gretchen Wells7, Aladdin H. Shadyab6, Rami Nassir8, Lisa Warsinger Martin9, JoAnn E. Manson10, 
Donald M. Lloyd‑Jones2, Philip Greenland2, Andrea A. Baccarelli11, Eric A. Whitsel12,13 and Lifang Hou2
Abstract 
Background: Cardiovascular health (CVH) has been defined by the American Heart Association (AHA) as the pres‑
ence of the “Life’s Simple 7” ideal lifestyle and clinical factors. CVH is known to predict longevity and freedom from 
cardiovascular disease, the leading cause of death for women in the United States. DNA methylation markers of aging 
have been aggregated into a composite epigenetic age score, which is associated with cardiovascular morbidity and 
mortality. However, it is unknown whether poor CVH is associated with acceleration of aging as measured by DNA 
methylation markers in epigenetic age.
Methods and results: We performed a cross‑sectional analysis of racially/ethnically diverse post‑menopausal 
women enrolled in the Women’s Health Initiative cohort recruited between 1993 and 1998. Epigenetic age accelera‑
tion (EAA) was calculated using DNA methylation data on a subset of participants and the published Horvath and 
Hannum methods for intrinsic and extrinsic EAA. CVH was calculated using the AHA measures of CVH contributing to 
a 7‑point score. We examined the association between CVH score and EAA using linear regression modeling adjust‑
ing for self‑reported race/ethnicity and education. Among the 2,170 participants analyzed, 50% were white and mean 
age was 64 (7 SD) years. Higher or more favorable CVH scores were associated with lower extrinsic EAA (~ 6 months 
younger age per 1 point higher CVH score, p < 0.0001), and lower intrinsic EAA (3 months younger age per 1 point 
higher CVH score, p < 0.028).
Conclusions: These cross‑sectional observations suggest a possible mechanism by which ideal CVH is associated 
with greater longevity.
Keywords: Cardiovascular health (CVH), Epigenetic age acceleration, Women’s health initiative (WHI), DNA 
methylation, Simple seven
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Introduction
In 2010, the American Heart Association defined the 
construct of ideal cardiovascular health (CVH) as the 
simultaneous presence of 7 ideal health factors: healthy 
diet, absence of smoking, healthy body mass index (BMI), 
and optimal levels of physical activity, blood pressure, 
fasting glucose, and total cholesterol [1]. Higher levels 
of CVH have been prospectively associated with greater 
longevity and healthy longevity, as well as markedly 
lower incidence of chronic diseases related to aging [1, 
2]. Higher CVH is also associated with lower incidence 
of cardiovascular disease [3], the leading cause of death 
among women in the United States [4]. Therefore, it is 
important to understand the biological mechanisms that 
may link CVH with favorable outcomes, which could 
assist novel biomarker discovery.
Open Access
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Epigenetic changes in patterns of DNA methylation 
are suggested as a promising mechanism, and epige-
netic aging as an important surrogate biomarker, in the 
research of aging, mortality, and chronic disease risk [5]. 
Epigenetic clocks are methods that have been used to 
evaluate epigenetic changes that lead to deviations from 
chronological age, a concept known as epigenetic age 
acceleration. Previous studies have shown that acceler-
ated epigenetic aging is predictive of poor health out-
comes [6, 7]. Although epigenetic age acceleration has 
been associated with individual components of CVH 
[8], its relationship with CVH as a whole has not been 
established. In this study, we investigated the relationship 
between CVH and epigenetic age acceleration by leverag-
ing an epidemiological cohort with objective assessment 
of CVH and blood DNA methylation data.
Results
There were 2170 individuals who were included in these 
analyses after the exclusion of individuals due to leu-
kemia diagnosis (n = 6), epigenetic age acceleration 
extremes (n = 10), and cardiovascular disease diagnosis 
(n = 14) (Fig.  1). Among the 2,170 WHI participants 
included in this study (Table 1), approximately 50% were 
non-Hispanic white, and most were non-smokers or quit 
smoking at least three-years prior to the blood draw. 
Proportionally, there were fewer non-Hispanic Black 
participants in the highest tertile of EEAA (faster aging) 
than lowest tertile, while there were more Hispanic par-
ticipants in the highest tertiles of EEAA than the lowest 
tertile (p < 0.001, Table 1). In the highest tertile of IEAA, 
there were fewer participants with an ideal BMI than the 
lowest tertile (Additional file 1: Table 1). This difference 
was, however, not statistically significant.
Participants with higher (more favorable) CVH score 
had lower EEAA (~ 6-month lower age per 1 point higher 
CVH score; p < 0.0001, Table  2). This association was 
consistent when analyzing IEAA (~ 3-month lower age 
per 1 point higher CVH score, p < 0.028, Table  2). For 
EEAA, a similar direction of association was seen when 
using the 3-level and 14-point definitions of CVH, with 
the 14-point definition showing a 2-month lower age 
per 1 point higher CVH (p < 0.0035, Additional file  1: 
Table  2). The 3-level definition of CVH, however, was 
Fig. 1 Flow diagram of individuals included for the analysis of cardiovascular health and epigenetic age acceleration
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not significantly associated with EEAA in this analy-
sis (p > 0.05, Additional file  1: Table  2). Additionally, for 
IEAA, the alternative definitions were not significant 
(both p > 0.05, Additional file 1: Table 2).
Discussion
In this study, we estimated the association between 
CVH at middle and older age and contemporaneous 
indicators of epigenetic age acceleration, leveraging 
data from 2170 post-menopausal women selected from 
the Women’s Health Initiative. We found that higher 
or more favorable CVH scores were associated with a 
lower extrinsic and intrinsic age acceleration among 
individuals without CVD. When multiple approaches 
to assess and quantify CVH were evaluated, the asso-
ciation between CVH and EEAA was consistent and 
similar, however, the association between CVH and 
IEAA was no longer significant. The loss of a statisti-
cal association between CVH and IEAA for 3-level and 
14-point scale model could be due to the change of the 
granularity of the data points that lead to a change in 
the linearity of the relationship. These data suggest that 
Table 1 Extrinsic epigenetic age acceleration cohort characteristics
Ref: reference group (T2/3 compared to T1); *p value < 0.05; ** p value < 0.01; *** p value < 0.001
BMI: body mass index; GED: general education diploma; CVH: cardiovascular health
Non-smoking: non-smokers or individuals who quit smoking three year prior to blood draw
Ideal cholesterol levels: cholesterol below 200 without medication
Ideal glucose levels: glucose below 100 without medication
Ideal BMI: BMI below 25
Ideal physical activity: greater than 150 min of moderate to strenuous activity or 75 min of strenuous activity
Ideal blood pressure: systolic blood pressure equal to or below 120, diastolic blood pressure below 80 without hypertension medication
Ideal diet: assessed based on calcium, potassium, fiber, and saturated fat intake




EEAA T3 (> 2.33 years.)
N 2170 724 727 719
Race/ethnicity (%)
Non‑Hispanic Black or African‑American 554 (25.53) 252 (34.81) 178 (24.48)*** 124 (17.25)***
Hispanic/Latino 315 (14.52) 62 (8.56) 117 (16.09)*** 136 (18.92)***
Non‑hispanic white 1083 (49.91) 356 (49.17) 352 (48.42) 375 (52.16)
Other 218 (10.05) 54 (7.46) 80 (11)* 84 (11.68)**
Chronological age years (sd.) 64.19 (7.06) 64.35 (7.11) 64.05 (7.09) 64.19 (7)
Education (%)
Less than high school 198 (9.2) 55 (7.66) 61 (8.46) 82 (11.5)
High school diploma or GED 395 (18.36) 108 (15.04) 141 (19.56)* 146 (20.48)**
Vocational, some college, associates 848 (39.41) 283 (39.42) 295 (40.92) 270 (37.87)
College degree or greater 711 (33.04) 272 (37.88) 224 (31.07)** 215 (30.15)**
Components of CVH score (%)
Non‑smoking 1,880 (87.81) 634 (88.55) 626 (87.31) 620 (87.57)
Ideal BMI 521 (24.13) 180 (25.07) 188 (25.9) 153 (21.4)
Ideal physical activity 428 (21.59) 150 (22.9) 153 (22.9) 125 (18.97)
Ideal cholesterol levels 1,536 (79.22) 505 (79.03) 514 (78.47) 517 (80.16)
Ideal glucose levels 1,928 (88.85) 657 (90.75) 640 (88.03) 631 (87.76)
Ideal blood pressure 414 (19.08) 147 (20.3) 133 (18.29) 134 (18.64)
Ideal diet 606 (27.93) 205 (28.31) 201 (27.65) 200 (27.82)
CVH score (%)
0–1 41 (2.16) 13 (2.07) 16 (2.48) 12 (1.91)
2 213 (11.2) 59 (9.39) 89 (13.82)** 65 (10.33)
3 636 (33.46) 213 (33.92) 188 (29.19) 235 (37.36)
4 574 (30.19) 186 (29.62) 207 (32.14) 181 (28.78)
5 294 (15.47) 104 (16.56) 94 (14.6) 96 (15.26)
6–7 143 (7.52) 53 (8.44) 50 (7.76) 40 (6.26)
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poor CVH could be acting through DNA methylation 
mechanisms to accelerate aging.
Previous studies have shown that factors similar to 
those included in the definition of CVH as well as the 
covariates used in these analyses, such as diet, physical 
activity, education and metabolic syndrome, are asso-
ciated with epigenetic changes [8, 9]. The magnitude of 
association is also comparable to previous studies [9]. 
While a healthy diet that includes regular consumption of 
fish, fruits, and vegetables showed a relatively weak cor-
relation with lower epigenetic aging, high education and 
high physical activity did have an association with lower 
extrinsic epigenetic age acceleration [8]. In addition, high 
body mass index, high triglycerides, and high blood pres-
sure are associated with higher extrinsic and intrinsic 
epigenetic age acceleration [8, 10]. Since these outcomes 
are associated with cardiometabolic changes, these data 
suggest that changes epigenetic age acceleration may be 
associated with cardiovascular outcomes [11]. However, 
similar to our study, these prior studies were cross-sec-
tional, and the temporality of association is unclear.
High CVH is known to be associated with lower mor-
tality for many outcomes including cardiovascular dis-
ease [3]. Epigenetic age acceleration has been shown 
to be associated with an increase in cardiovascular dis-
ease mortality and all-cause mortality [6]. Conceptually, 
intrinsic epigenetic age is thought to be stable and not 
changed by external changes in the environment such as 
behavior and lifestyle changes and is often more related 
to chronological aging. Conversely, extrinsic epigenetic 
age is thought to be more influenced by environmental 
and lifestyle factors [12]. The strong association of CVH 
with extrinsic epigenetic age acceleration that we observe 
in these analyses could be affected by the lifestyle fac-
tors that are used to calculate the CVH scores. However, 
precise quantification of diet and physical activity is 
difficult. Therefore, extrinsic epigenetic age accelera-
tion could be a more sensitive biomarker for CVH than 
intrinsic epigenetic age acceleration.
The strength of this study includes the availability of 
DNA methylation data on a moderately to large-sized 
sample of women. Additionally, we analyzed CVH utiliz-
ing the AHA’s “Life’s Simple 7” ideal lifestyle and clinical 
factors as a single metric rather than using the individ-
ual components as many of these factors are correlated. 
Limitations include lack of generalizability of the results 
to men or younger women. We were able to analyze 
measures that were temporally proximate to those of 
DNA methylation age acceleration. However, as this is a 
cross-sectional design, causality could not be established. 
Future studies could consider the amount of time that 
would be adequate to observe epigenetic changes after 
positive lifestyle changes. In addition, DNA methyla-
tion clocks present challenges for integrating values for 
clinical utility which could be improved by increasing the 
population size of the training data used to make infer-
ences as well as increase the ancestral diversity of these 
data [13, 14]. Furthermore, it is difficult to assess causal-
ity between DNA methylation age acceleration and out-
come. As such, additional methods to establish causal 
relationships have been utilized to explore the causality 
[15, 16].
Conclusions
This research shows an association between CVH and 
epigenetic age acceleration. This work provides initial 
evidence for epigenetic age acceleration to be consid-
ered as a potential early detection biomarker for CVH. 
Future studies are needed to evaluate if measures to 
promote optimal CVH through lifestyle and behavio-
ral interventions could substantially alter an individual’s 
epigenetic signature and the clinical utility of such a sig-
nature. In future, epigenetic data have the possibility to 
provide novel information that could be used in addition 
to genetic information, such as polygenic risk scores, to 




The Women’s Health Initiative (WHI) is a cohort of 
post-menopausal women who were enrolled from 1993 
to 1998 and were initially between the ages of 50 and 
79  years. Inclusion and exclusion criteria for participa-
tion in the WHI study have been described [17]. From 
the overall WHI cohort, a stratified, racially/ethnically 
diverse sample of 2200 WHI clinical trial participants 
with available stored serum were selected for DNA 
Table 2 Results of  regression analysis of  extrinsic 
and  intrinsic epigenetic age acceleration on  ideal health 
score among  participants free of  cardiovascular disease 
at DNA methylation blood draw
EEAA: extrinsic epigenetic age acceleration; IEAA: intrinsic epigenetic age 
acceleration
Results are adjusted for self-reported race/ethnicity and education










− 0.209 (years) 0.0956 0.0283
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methylation analysis at either the screening visit or 
annual visits [15]. A description of the clinical trials has 
been published [17]. Briefly, data were collected on par-
ticipant demographics, and health outcomes through 
questionnaire and clinical examination on initial and 
follow-up visits. Baseline blood samples were collected 
from participants in EDTA tubes after an overnight fast. 
These specimens were stored at – 70 °C and processed by 
the WHI core laboratories [8]. Data used for this analy-
sis were from the closest visit date preceding or on the 
date of blood draw for DNA methylation analysis (64% of 
which were on the same day, 30% within 2–5 years, and 
6% within 5–7 years earlier).
Measurements
Outcome
DNA Methylation Data. DNA methylation assays were 
performed using the Illumina Infinium Human-Meth-
ylation450 Bead Chip [18] and was conducted at the 
HudsonAlpha Institute of Biotechnology. Genome-wide 
DNA methylation data was used to estimate epigenetic 
age (DNAm) using the proportion of modified signal at 
each CpG site. Horvath’s [19] and Hannum methods [20] 
were used to calculate intrinsic and extrinsic epigenetic 
age acceleration, respectively. Intrinsic epigenetic age 
acceleration (IEAA) is a residual value calculated from 
regressing DNAm age using 353 CpGs on blood cell 
counts of naïve and exhausted CD8 + T cells, CD4 + T 
cells, plasma B cells, natural killer cells, monocytes, and 
granulocytes [21]. Extrinsic epigenetic age acceleration 
(EEAA) was calculated using DNAm age using 71 CpGs, 
and cell counts of naïve and exhausted cytotoxic T cells, 
and plasma B cells- cell types that are known to be asso-
ciated with age. A linear regression model that regressed 
on the weighted estimated age was used to generate 
residual values of acceleration [8]. Methylation data from 
an individual with a leukemia diagnosis would introduce 
bias in the methylation analyses. Therefore, individu-
als with a leukemia diagnosis were removed from these 
analyses.
Exposure: cardiovascular health score
The CVH score was calculated based on the American 
Heart Association “Life’s Simple Seven” measures for 
CVH [1]. These seven factors include diet, physical activ-
ity, smoking status, BMI, blood pressure, fasting glucose, 
and total cholesterol. The clinical and behavioral meth-
ods that contribute to CVH were defined, scored, and 
summed to create an ideal cardiovascular health score as 
in Foraker, et al. [2]. An individual was assigned a score 
of 1 for each ideal value for the category described gen-
erating a minimum score of 0 and a maximum score of 7. 
For example, if an individual had an ideal glucose level, a 
fasting glucose of less than 100 without medication, they 
were assigned a score of 1 for ideal glucose. An individual 
with a fasting glucose level greater than 100, or an indi-
vidual who received treatment for diabetes, was assigned 
a score of 0. Ideal values for each category can be found 
in the footnote of Table  1, Additional file  1: Fig.  1, and 
Table 1. Individuals with a score of 0 or 1 were combined 
into a single stratum, as were individuals with a score of 
6 or 7. Individuals with a higher score had better or more 
favorable cardiovascular health. Sensitivity analyses were 
performed to include other definitions of CVH including 
a 14-point definition in which 0 to 2 points were assigned 
to each of the “Life’s Simple 7” metrics (0 for poor, 1 
for intermediate, 2 for ideal) and treated as continu-
ous, and a 3-level definition which is a collapsed version 
of the 14-point score (low = 1–7; intermediate = 8–11; 
high = 12–14).
Statistical analysis
To describe baseline characteristics and CVH score, the 
cohort was divided into tertiles of EEAA/IEAA. The CVH 
7-point score metric was used as the exposure variable 
to test for relationships with intrinsic and extrinsic age 
acceleration in a multivariable linear regression model, 
adjusting for self-reported race/ethnicity and education. 
Values for covariates were calculated before or at the 
time of blood draw. Sensitivity analyses were conducted 
using the 3-level definition of CVH and the 14-point defi-
nition of CVH in a multivariable linear regression model, 
adjusting for self-reported race/ethnicity and education. 
Individuals with values of epigenetic age acceleration 
greater than 25 or less than – 25 were excluded in these 
analyses to reduce the statistical deviations. The software 
package SAS 9.4 was used for this analysis.
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